

Resource Summary Report

Generated by [dkNET](#) on Sep 8, 2026

HCC1187

RRID:CVCL_1247

Type: Cell Line

Proper Citation

RRID:CVCL_1247

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1247

Proper Citation: RRID:CVCL_1247

Description: Cell line HCC1187 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Defining Citation: [PMID:9833771](#), [PMID:9865903](#), [PMID:11314036](#), [PMID:12800145](#), [PMID:16959974](#), [PMID:17157791](#), [PMID:17932254](#), [PMID:19582160](#), [PMID:20164919](#), [PMID:21778573](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23151021](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Group: Triple negative breast cancer (TNBC) cell line.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC1187

Synonyms: HCC-1187, Hamon Cancer Center 1187

Cross References: CLO:CLO_0003632, EFO:EFO_0001170, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-

3610, ArrayExpress:E-TABM-157, ATCC:CRL-2322, BioGRID_ORCS_Cell_line:874, BioSample:SAMN03471273, BioSample:SAMN10987946, cancercellines:CVCL_1247, Cell_Model_Passport:SIDM00885, ChEMBL-Cells:ChEMBL3308845, ChEMBL-Targets:ChEMBL2366202, CLS:305781, Cosmic:749711, Cosmic:904361, Cosmic:1136366, Cosmic:1235080, Cosmic:1287916, Cosmic:1430348, Cosmic:1460231, Cosmic:1473100, Cosmic:1518110, Cosmic:1603199, Cosmic:1995422, Cosmic-CLP:749711, dbGAP:phs001839.v1.p1, DepMap:ACH-000111, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, GDSC:749711, GEO:GSM185077, GEO:GSM185078, GEO:GSM186712, GEO:GSM186713, GEO:GSM217571, GEO:GSM219916, GEO:GSM344370, GEO:GSM344420, GEO:GSM350540, GEO:GSM378152, GEO:GSM783933, GEO:GSM844542, GEO:GSM847320, GEO:GSM847473, GEO:GSM887035, GEO:GSM888105, GEO:GSM1008896, GEO:GSM1053708, GEO:GSM1172956, GEO:GSM1214579, GEO:GSM1374494, GEO:GSM1374495, GEO:GSM1401672, GEO:GSM1661979, GEO:GSM1669842, IARC_TP53:21360, IARC_TP53:22810, IARC_TP53:30201, LiGeA:CCLE_850, LINCS_HMS:50578, LINCS_LDP:LCL-1324, PharmacDB:HCC1187_469_2019, PRIDE:PXD030304, Progenetix:CVCL_1247, PubChem_Cell_line:CVCL_1247, SLKBase:3507, Wikidata:Q54881536

ID: CVCL_1247

Record Creation Time: 20220427T220317+0000

Record Last Update: 20260905T180216+0000

Ratings and Alerts

No rating or validation information has been found for HCC1187.

No alerts have been found for HCC1187.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 121 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Esapa B, et al. (2026) An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. NPJ precision oncology, 10(1).

Patel SS, et al. (2025) Induction of Triple-Negative Breast Cancer Cell Death and Chemosensitivity Using mTORC2-Directed RNAi Nanomedicine. Cancer research communications, 5(3), 458.

Vykoukal J, et al. (2025) Vesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer. *Cell reports. Medicine*, 6(12), 102478.

Schreiber AR, et al. (2025) Potentiating doxorubicin activity through BCL-2 inhibition in p53 wild-type and mutated triple-negative breast cancer. *Frontiers in oncology*, 15, 1549282.

Waas M, et al. (2024) Droplet-based proteomics reveals CD36 as a marker for progenitors in mammary basal epithelium. *Cell reports methods*, 4(4), 100741.

Roche S, et al. (2023) Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and Insulin Receptor (IR) as a therapeutic targets in triple negative breast cancer. *PloS one*, 18(3), e0282512.

Xie X, et al. (2023) Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. *Biomedicines*, 11(3).

Boyd DC, et al. (2023) Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. *Cancers*, 15(5).

Kj??lle S, et al. (2023) Hypoxia induced responses are reflected in the stromal proteome of breast cancer. *Nature communications*, 14(1), 3724.

Bhattacharya U, et al. (2023) Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide. *Cancers*, 15(2).

Stefanski CD, et al. (2023) APC Loss Prevents Doxorubicin-Induced Cell Death by Increasing Drug Efflux and a Chemoresistant Cell Population in Breast Cancer. *International journal of molecular sciences*, 24(8).

Limsakul P, et al. (2023) Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. *Cancers*, 15(2).

Hoogenboezem EN, et al. (2023) Structural Optimization of siRNA Conjugates for Albumin Binding Achieves Effective MCL1-Targeted Cancer Therapy. *bioRxiv : the preprint server for biology*.

Liu Y, et al. (2023) Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial. *Cell research*, 33(5), 389.

Jovanovi?? B, et al. (2023) Heterogeneity and transcriptional drivers of triple-negative breast cancer. *Cell reports*, 42(12), 113564.

Kim H, et al. (2023) Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages. *Cell reports*, 42(10), 113256.

Hardeman AA, et al. (2022) Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. *PloS one*, 17(6), e0268693.

Sun Q, et al. (2022) Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1. NPJ breast cancer, 8(1), 5.

Montero JC, et al. (2022) Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer. Journal of experimental & clinical cancer research : CR, 41(1), 106.

Kuhlmann L, et al. (2022) Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. Journal of proteome research, 21(9), 2224.